Application of soluble Tim3 in immune checkpoint blocking treatment resistance

The invention provides application of soluble Tim3 in immune checkpoint blocking treatment resistance, and belongs to the technical field of biological medicine and molecular biology. According to the invention, it is found that the soluble Tim3 not only is remarkably up-regulated in NSCLC which is not responded to PD-1 blocking treatment, but also shows a relatively high serum level in bile duct cancer, and the bile duct cancer is reported to have relatively high resistance to PD-1 blocking treatment. Importantly, the sTim-3 is found to induce a PD-1 antibody to block treatment resistance in an ICC mouse model, and the T cell function is inhibited in a CEACAM1 dependency mode, so that tumor progression is promoted. Therefore, the human sTim-3 can be used as a candidate biomarker for tumor progression and PD-1 blocking treatment drug resistance, a new mechanism of Tim-3 mediated immunosuppression and PD-1 blocking treatment resistance in a tumor environment is provided, and the human sTim-3 has good practical